Civitas Therapeutics, Inc., a biopharmaceutical company, develops and commercializes transformative therapeutics using its ARCUS technology. Its technology enables the delivery of a precise dose to the lung to potentially enable rapid and predictable L-dopa absorption through a reusable, pocket-size, and breath-actuated inhaler. The company offers CVT-301, a inhaled L-dopa therapy for OFF episodes that provides rapid delivery of L-dopa to the brain to be used in conjunction with a Parkinson’s disease patient’s individually optimized oral L-dopa regimen. Civitas Therapeutics, Inc. was formerly known as Corregidor Therapeutics, Inc. and changed its name to Civitas Therapeutics, Inc. in April 2011. The company was founded in 2009 and is based in Chelsea, Massachusetts. As of October 22, 2014, Civitas Therapeutics, Inc. operates as a subsidiary of Acorda Therapeutics, Inc. On April 1, 2024, Civitas Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. The plan was later approved as Chapter 11 liquidation on August 7, 2024. It is in joint administration with Acorda Therapeutics, Inc.